In the face of constrained R&D budgets, a top-5 pharmaceutical company needed support to develop a transformative, corporate-wide strategy to assess and secure external funding.
Industry
Developing a Therapeutic Vaccine of Greatest Value to Patients and Systems
A top-5 pharmaceutical company sought the perspectives of payers in the US and major EU markets to ensure that the value of an innovative vaccine would ultimately be recognized by health systems.
Inspiring Urgency Needed to Tackle Alzheimer’s Disease
A top-5 pharmaceutical company needed to prepare decision-makers for the patient and health system impact of disease-modifying therapies and diagnostic biomarkers for Alzheimer’s disease.
Uncovering Risks and Forecasting Performance of a Royalty Portfolio to Guide Investment Decisions
A large institutional investment firm engaged Shift Health to evaluate the products in a portfolio of pharma royalties it had an opportunity to acquire.
Positioning a Global Pharmaceutical Company’s HIV Portfolio to Capture Emerging Opportunities
Shift Health was engaged to support a top-5 global pharmaceutical company in defining its role and priorities in the evolving HIV disease management landscape.
Accelerating R&D Efforts Through Patient Data Repository Partnerships
A multinational pharmaceutical company sought support in developing a strategy to partner with public/academic cancer patient data repositories to advance its own R&D programs.
De-Risking Vaccine Development Through a Translational Research Public-Private Partnership
Facing the need to de-risk the development of new vaccines, a top-10 biopharma company required help articulating the strategic vision and business case for a translational research public-private partnership.
Ensuring the World is Ready for the World’s First HIV Vaccine
The Pox-Protein Public-Private Partnership (P5) is tackling an enduring and daunting challenge: developing the world’s first HIV vaccine and ensuring it achieves maximum public health impact.
Preparing Policymakers for the Next Generation of Personalized Medicine
A large biotech firm needed support in developing an evidence-based policy narrative in preparation for the launch of a CAR T-cell therapy for a rare form of cancer.